Welcome to our dedicated page for Elevation Oncolo news (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncolo stock.
Elevation Oncology, Inc. (formerly Nasdaq: ELEV) has generated a range of news focused on its efforts to develop selective cancer therapies for solid tumors with significant unmet medical needs and on its subsequent corporate transformation. Company press releases highlight its concentration on antibody-drug conjugate (ADC) programs targeting Claudin 18.2 and HER3, as well as key corporate and transactional milestones.
Earlier news coverage centers on Elevation Oncology’s pipeline updates and scientific progress. The company reported clinical and preclinical developments for EO-3021, a Claudin 18.2 ADC evaluated in a Phase 1 trial for advanced gastric and gastroesophageal junction adenocarcinoma, including monotherapy and combination cohorts with ramucirumab and dostarlimab. It also announced preclinical proof-of-concept data and development plans for EO-1022, a HER3-targeting ADC designed for HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer, and described licensing of a site-specific ADC technology platform from Synaffix B.V.
Subsequent news includes strategic decisions and corporate restructuring. On March 20, 2025, Elevation Oncology disclosed that it would discontinue development of EO-3021 after evaluating updated Phase 1 data, and that it would implement a significant workforce reduction while focusing on EO-1022 and evaluating strategic options. Financial results releases have provided context on research and development spending, general and administrative expenses, restructuring charges, and cash runway expectations, as reported by the company.
A major news development occurred on June 9, 2025, when Elevation Oncology announced a definitive merger agreement under which Concentra Biosciences, LLC would acquire the company through a tender offer and subsequent merger, with shareholders receiving cash consideration and a non-tradeable contingent value right. A later Form 8-K dated July 23, 2025 confirms completion of the tender offer and merger, after which Elevation Oncology became a wholly owned subsidiary of Concentra and moved to delist and deregister its common stock.
Readers following historical ELEV news can review these updates to understand Elevation Oncology’s scientific focus on ADCs, its program-level decisions, financial disclosures, participation in scientific and investor conferences, and the steps that led to its acquisition and transition away from public trading.
Elevation Oncology (Nasdaq: ELEV) reported its financial results for Q4 2022, revealing a net loss of $19 million, up from $9.6 million in Q4 2021. The company has $90.3 million in cash and equivalents, sufficient to fund operations into Q4 2024. Key developments include the prioritization of EO-3021, a promising antibody-drug conjugate targeting solid tumors with Claudin 18.2, with preclinical data expected in H1 2023 and the initiation of a Phase 1 trial in the US in H2 2023. Additionally, there has been a workforce reduction of about 30% and a pause in investment in seribantumab's clinical development.
Elevation Oncology (Nasdaq: ELEV) announced participation in key investor conferences this March. They will attend the Cowen 43rd Annual Health Care Conference on March 7 at 12:50 p.m. ET focusing on GI/GU Oncology. Additionally, they will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15 at 8:00 a.m. ET. A live webcast and replay will be accessible on their Investor Relations website. Elevation Oncology is dedicated to developing selective cancer therapies, like their lead candidate, EO-3021, targeting Claudin18.2.
Elevation Oncology, Inc. (Nasdaq: ELEV) announced that Interim CEO Joseph Ferra will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 4:20 pm ET. The event will feature a live webcast available on the Company's Investor Relations website.
Elevation Oncology focuses on developing selective cancer therapies for patients with significant unmet medical needs. Its lead candidate, EO-3021, aims to target Claudin18.2, delivering a cytotoxic payload directly to cancer cells. The company is advancing EO-3021 into clinical trials in the US across multiple solid tumor indications.
Elevation Oncology, Inc. (Nasdaq: ELEV) announced that Joseph Ferra, Interim CEO and CFO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 9:45 am PT. The event will be accessible via a live webcast on the Company's Investor Relations website. Elevation Oncology focuses on developing selective cancer therapies for solid tumors, with its lead candidate, EO-3021, targeting Claudin18.2.
Elevation Oncology (Nasdaq: ELEV) announced a strategic shift prioritizing EO-3021, a potential best-in-class antibody-drug conjugate (ADC) targeting Claudin18.2, and other pipeline programs. The company will pause further investment in seribantumab, seeking future development partnerships. A leadership change occurred with Joseph Ferra appointed as Interim CEO following Shawn Leland's resignation. Additionally, Elevation plans a 30% workforce reduction to extend its cash runway into Q4 2024, supported by a cash position of approximately $90.3 million as of December 31, 2022.
Elevation Oncology, Inc. (Nasdaq: ELEV) announced that Shawn M. Leland, CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 11:00 am ET. This event will be webcast live, and a replay will be available on the Company's Investor Relations website. Elevation Oncology focuses on developing precision medicines for genomically defined cancers, with key products like seribantumab and EO-3021.
Elevation Oncology (Nasdaq: ELEV) announced its financial results for Q3 2022, reporting a net loss of $38.8 million, compared to $12.3 million in Q3 2021. Cash, cash equivalents, and marketable securities totaled $107.9 million, down from $122.5 million. The company is progressing with the Phase 2 CRESTONE study for seribantumab, expecting to report additional interim data in H1 2023. Additionally, preparations are underway for a Phase 1 clinical trial of EO-3021 in solid tumors in 2023. Elevation Oncology anticipates that existing cash will fund operations into 2024.
Elevation Oncology (ELEV) announced its Q2 2022 financial results, highlighting significant progress in its clinical pipeline. The presentation of the Phase 2 CRESTONE study data for seribantumab showcased a 33% response rate among evaluable patients with NRG1 fusions. Elevation secured Fast Track designation from the FDA for seribantumab and executed a licensing deal for EO-3021, targeting Claudin18.2, with a $27 million upfront payment. The company reported a net loss of $19.9 million and had $122.5 million in cash as of June 30, 2022.
Elevation Oncology, Inc. (Nasdaq: ELEV) announced that CEO Shawn M. Leland will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference on August 9, 2022, at 10:55 am ET. The event will be available via live webcast on the Company's Investor Relations website. Elevation Oncology focuses on developing precision medicines for patients with genomically defined cancers, with its leading candidate, seribantumab, targeting NRG1 fusions in solid tumors. Additional information can be found on their website.
Elevation Oncology, Inc. (Nasdaq: ELEV) has secured a $50 million senior secured loan facility from K2 HealthVentures. The initial $30 million tranche will primarily fund the exclusive licensing of EO-3021 (SYSA1801) outside Greater China from CSPC Pharmaceutical Group. This move aims to enhance Elevation's clinical oncology pipeline and financial flexibility. The company expects its cash reserves to support operations into 2024, with future proceeds potentially backing ongoing development and expansion efforts.